First-line tremelimumab plus durvalumab and chemotherapy versus chemotherapy alone for metastatic non-small cell lung cancer: a cost-effectiveness analysis in the United States

Importance: In the open-label phase III POSEIDON randomized clinical trial (RCT), a limited course of tremelimumab plus durvalumab and chemotherapy (T + D + CT) indicated in the first-line treatment of metastatic non-small cell lung cancer (mNSCLC), progression-free survival, and overall survival (O...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wenjie, Huo, Gengwei, Chen, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398575/
https://www.ncbi.nlm.nih.gov/pubmed/37547328
http://dx.doi.org/10.3389/fphar.2023.1163381

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10398575/
https://www.ncbi.nlm.nih.gov/pubmed/37547328
http://dx.doi.org/10.3389/fphar.2023.1163381

Ejemplares similares